Comments on therapeutic cancer vaccines

Immunotherapy

Volumn 4, Issue 2, 2012, Pages 133-135

  Vonka, Vladimr ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

allogenic cell lines; cancer; vaccines

Indexed keywords

ANGIOGENIC FACTOR; BCR ABL PROTEIN; CANCER VACCINE; DENDRITIC CELL VACCINE; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; ONCOPROTEIN; PROTEIN E6; PROTEIN E7; RECOMBINANT VACCINE;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNITY; IMMUNOCOMPETENT CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; WART VIRUS;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; INDIVIDUALIZED MEDICINE; MODELS, ANIMAL; NEOPLASMS; PEPTIDE FRAGMENTS; VACCINES, DNA;

EID: 84857609579     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.173     Document Type: Review

References (19)

1. Grünebach F, Mirakaj V, Mirakaj V, Müller MR, Brümendorf T, Brossart P. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia. Cancer Res. 66, 5892-5890 (2006).
2. Brauer KM, Werth D, von Schwarzenberg K et al. BCR-ABL activity is critical for the immunogenicity of chronic myeloid leukemia cells. Cancer Res. 67, 5892-5900 (2007).
3. Su J, Wu A, Scootney E et al. Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs 24, 109-129 (2010).
4. Šímová J, MikyŠková R, Vonka V, Bieblová J, Bubeník J, Jandlová T. MHC class I+ and class I- HPV16-associated tumors expressing E7 protein do not cross-react in immunization/challenge experiments. Folia Biol. (Praha) 49, 230-234 (2003).
5. LakatoŠová-Andělová M, Jinoch P, DuŠková M, Marinov I, Vonka V. Live cell vaccines expressing B7.1, monocyte-chamoattractant protein 1 and granulocyte-macrophage colony stimulating factor derived from mouse HPV16-transformed cells. Int. J. Oncol. 32, 265-271 (2008).
6. Pittet M. Behaviour of immune players in the tumor environment. Curr. Opin Oncol. 21, 53-59 (2009).
7. Järäs K, Anderson K. Autoantibodies in cancer: Prognostic biomarkers and immune activation. Exp. Rev. Proteomics 8, 577-589 (2011).
8. Chen CL, Maecker HT, Lee P. Development and dynamics of robust T cell response to CML under imatinib treatment. Blood 111, 5342-5349 (2008).
9. Bronte V, Mocellin S. Suppressive influences in the immune response to cancer. J. Immunother. 32, 1-11 (2009).
10. Dore M. Cyclogenase?2 expression in animal cancers. Vet. Pathol. 48, 254-265 (2010).
11. Soliman H, Madiavella-Varella M. Indolamine-2,3 dioxygenase: Is it an immune suppressor? Cancer J. 16, 354-359 (2010).
12. Di Costanzo L, Illies M, Thorn KJ, Christianson DW. Inhibition of human arginase I by substrate and product analogues. Arch. Biochem. Biophys. 496, 101-108 (2010).
13. Lewen S, Zhou H, Hu HD et al. A legumani-based minigene vaccine targets the tumor stroma and suppresss breast cancer growth and angiogenesis. Cancer Immunol. Immunother. 57, 507-515 (2008).
14. Subado RI, Bhardwaj N. Directing dendritic cells toward successful cancer treatment. Immunotherapy 2, 37-56 (2010).
15. Dranoff G. GM?CSF-based cancer vaccines. Immunol. Rev. 188, 147-154 (2002).
16. Balashova EE, Dashtiev M, Lokhov PG. Proteomic footprinting of drug-treated cancer cells as a measure of cellular vaccine efficacy for the prevention of cancer recurrences. Mol. Cell. Proteomics doi:10.1074/mcp.M111. 014480 (2011) (Epub ahead of print).
17. Li B, Simmons A, Du T et al. Allogenic GM?CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies. Clin. Immunol. 133, 184-197 (2009).
18. Vonka,V. Immunotherapy of chronic myeloid leukemia: Present state and future prospects. Immunotherapy 2, 227-241 (2010).
19. Smahel M. Antigens in chronic myeloid leukemia: Implications for vaccine development. Cancer Immunol. Immunother. 60(12), 1655-1668 (2011).